BlackRock Inc. increased its position in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 2.5% during the 4th quarter, Holdings Channel reports. The firm owned 3,106,298 shares of the biotechnology company’s stock after purchasing an additional 75,255 shares during the period. BlackRock Inc. owned 0.08% of Spark Therapeutics worth $121,580,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Pearl River Capital LLC acquired a new stake in Spark Therapeutics in the fourth quarter worth $31,000. Quantamental Technologies LLC acquired a new stake in Spark Therapeutics in the fourth quarter worth $126,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Spark Therapeutics by 16.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock worth $135,000 after buying an additional 485 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Spark Therapeutics by 103.4% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,718 shares of the biotechnology company’s stock worth $141,000 after buying an additional 1,890 shares during the period. Finally, SG Americas Securities LLC increased its position in Spark Therapeutics by 7.0% in the fourth quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock worth $188,000 after buying an additional 313 shares during the period.
Several brokerages have weighed in on ONCE. William Blair lowered Spark Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 7th. SunTrust Banks lowered Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 25th. Raymond James lowered Spark Therapeutics from a “strong-buy” rating to a “market perform” rating in a research report on Monday, February 25th. ValuEngine raised Spark Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 25th. Finally, Jefferies Financial Group lowered Spark Therapeutics from a “buy” rating to a “hold” rating and increased their target price for the stock from $85.00 to $114.50 in a research report on Tuesday, February 26th. Eighteen analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $79.07.
Shares of ONCE opened at $113.53 on Tuesday. The firm has a market cap of $4.29 billion, a PE ratio of -53.81 and a beta of 2.59. The company has a current ratio of 9.10, a quick ratio of 8.68 and a debt-to-equity ratio of 0.09. Spark Therapeutics Inc has a one year low of $34.53 and a one year high of $114.20.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, February 19th. The biotechnology company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.89). The business had revenue of $13.15 million for the quarter, compared to analyst estimates of $26.76 million. Spark Therapeutics had a negative net margin of 121.78% and a negative return on equity of 14.94%. Spark Therapeutics’s revenue for the quarter was up 47.9% on a year-over-year basis. During the same period last year, the business posted ($1.63) earnings per share. Sell-side analysts anticipate that Spark Therapeutics Inc will post -4.52 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Spark Therapeutics Inc (ONCE) Shares Bought by BlackRock Inc.” was originally reported by Highlight Press and is the sole property of of Highlight Press. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://highlightpress.com/2019/03/26/spark-therapeutics-inc-once-shares-bought-by-blackrock-inc.html.
Spark Therapeutics Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Featured Article: How to Profit and Limit Losses With Stop Orders
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.